Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €23.47 EUR
Change Today -0.025 / -0.11%
Volume 115.0
AB3A On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:56 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (AB3A) Snapshot

Open
€23.12
Previous Close
€23.50
Day High
€23.47
Day Low
€22.69
52 Week High
05/30/14 - €26.00
52 Week Low
01/14/15 - €9.62
Market Cap
973.4M
Average Volume 10 Days
1.7K
EPS TTM
--
Shares Outstanding
41.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAREPTA THERAPEUTICS INC (AB3A)

sarepta therapeutics inc (AB3A) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

204 Employees
Last Reported Date: 02/26/15
Founded in 1980

sarepta therapeutics inc (AB3A) Top Compensated Officers

Interim Chief Executive Officer, Chief Medica...
Total Annual Compensation: $399.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $443.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $393.4K
Senior Vice President of Technical Operations
Total Annual Compensation: $335.9K
Compensation as of Fiscal Year 2014.

sarepta therapeutics inc (AB3A) Key Developments

Sarepta Therapeutics, Inc. Announces Plans to Submit Rolling NDA for Eteplirsen following Today’s Pre-NDA Meeting with the FDA

Sarepta Therapeutics, Inc. announced that the company held a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding its lead product candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy (DMD). The company has agreed with the Agency to initiate a rolling NDA submission and will submit the non-clinical and CMC components of the NDA by the end of this week. As previously announced, the company plans to submit the final component of the NDA by mid-year 2015.

Sarepta Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Sarepta Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported operating loss of USD 61.862 million compared to USD 25.121 million a year ago. Net loss was USD 61.559 million compared to USD 28.273 million a year ago. Basic and diluted net loss per share was USD 1.49 compared to USD 0.75 a year ago. Non GAAP net loss was USD 47.403 million compared to USD 20.671 million a year ago. Basic and diluted non-GAAP net loss per share was USD 1.15 compared to USD 0.55 a year ago. The incremental loss of USD 26.7 million was primarily the result of increased operating expenses as well as a decrease in revenue from the Company's government contracts.

Sarepta Therapeutics, Inc. to Report Q1, 2015 Results on May 07, 2015

Sarepta Therapeutics, Inc. announced that they will report Q1, 2015 results at 8:00 AM, US Eastern Standard Time on May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €23.47 EUR -0.025

AB3A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,373 GBp -119.50
Baxter International Inc $66.61 USD -0.54
GlaxoSmithKline PLC 1,454 GBp -6.50
Hemispherx Biopharma Inc $0.23 USD -0.007
SciClone Pharmaceuticals Inc $9.26 USD -0.21
View Industry Companies
 

Industry Analysis

AB3A

Industry Average

Valuation AB3A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 287.3x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 241.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit www.sareptatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.